Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay
With Sandoz delivering first-quarter growth thanks to its booming biosimilars business – and despite flat sales of small-molecule generics that suffered from a downturn in North America – the company is “well on track to surf the biosimilars wave,” according to one analyst. However, Sandoz did report a delay to progress with its natalizumab biosimilar in the US that will push back launch.
Henlius Reports Revenue Rise For First Quarter Of 2024
The Chinese biotech reported increased growth in its revenue fuelled by its portfolio of biologic drugs and biosimilars, with further plans for approvals around the world.
Pfizer Takes A Hit On US Oncology Biosimilars In Q1
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing pressures took their toll.
Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results
Amgen has revealed a program for a biosimilar rival to Keytruda, as it reported Q1 results that saw its biosimilars business grow by more than a tenth.
Milestone Payments Fuel Growth For Formycon In 2023
Formycon has shared its results for 2023, reporting revenue growth and exceeding projections for its working capital, as the company prepares for approvals in the coming year.
Hikma Strikes AG Nucynta Agreement As Clock Ticks On Opioid’s IP Life
Hikma will look to guarantee US generic competition to the powerful opioid brand Nucynta, albeit in the form of an authorized generic, as questions swirl over the appetite of at least one ANDA filer to compete on an equal footing, per the terms of a patent-litigation settlement deal.
No Takers For Biogen’s Biosimilars Business?
It’s been a year since Biogen made it clear that it was ready to put its biosimilars business on the market. But despite signaling interest in the unit from multiple potential suitors over the past 12 months, the firm says it hasn’t yet received any “acceptable” offers, and may retain it after all.
Mallinckrodt Reports 2023 Results After Second Restructuring
Emerging out of its second Chapter 11 bankruptcy filing in the past four years, the company reported a slump in net sales despite positive signals in specific portfolios.
Henlius Reports First Fully Profitable Year After Past Losses
After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.
Hyloris Reports 44% Revenue Growth Driven By Royalties In 2023
Belgian company Hyloris Pharmaceuticals has reported a 44% revenue increase in its 2023 results while doubling down on its long-standing ambition to have 30 portfolio assets in the near future.
Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing
Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.
Is Stada Laying The Ground For Future Sale With Russia Business Spin Off?
With the war in Ukraine now in its third gruelling year, Stada has announced that it last year siphoned off its Russian interests to its parent company Nidda in a non-cash deal.
Coherus: Udenyca Trajectory ‘Unknown’ But ‘Compelling’ With On-Body Launch
Coherus BioSciences has spoken in detail about its full suite of Udenyca pegfilgrastim biosimilar products and how it plans to return to growth and positive cash flow moving forward – although it cannot, for now, provide an estimate for 2024 revenues.
Endo’s Bleak Financial Reality May See Hope In Spring Amid Potential Restructuring
Endo’s generic and injectable segments struggled last year, with even lower projections for 2024, but potential financial restructuring may help the company rise from the ashes.
Sandoz Benefits From Betting Big On Biosimilars
Sandoz’s biosimilars business was a big earner for the company in 2023. During the firm’s Q4 results call, CEO Richard Saynor provided a detailed breakdown of key products in the biosimilars portfolio and pipeline, as he highlighted sales growth of 26% in the most recent quarter.
Sandoz Celebrates Growth As It Delivers First Standalone Annuals
An upbeat Sandoz pointed to growth across all its regions and businesses in 2023, as the firm delivered its first annual results as a standalone company.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.